|
1
|
Berruti A, Generali D, Bertaglia V, Brizzi
MP, Mele T, Dogliotti L, Bruzzi P and Bottini A: Intermediate
endpoints of primary systemic therapy in breast cancer patients. J
Natl Cancer Inst Monogr. 2011:142–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Berruti A, Generali D, Kaufmann M, Puztai
L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou
C, et al: International expert consensus on primary systemic
therapy in the management of early breast cancer: Highlights of the
Fourth Symposium on Primary Systemic Therapy in the Management of
Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst
Monogr. 2011:147–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gralow JR, Burstein HJ, Wood W, Hortobagyi
GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF,
Singh B and Winer EP: Preoperative therapy in invasive breast
cancer: Pathologic assessment and systemic therapy issues in
operable disease. J Clin Oncol. 26:814–819. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weigelt B, Baehner FL and Reis-Filho JS:
The contribution of gene expression profiling to breast cancer
classification, prognostication and prediction: A retrospective of
the last decade. J Pathol. 220:263–280. 2010.PubMed/NCBI
|
|
5
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Turner NC and Reis-Filho JS: Tackling the
diversity of triple-negative breast cancer. Clin Cancer Res.
19:6380–6388. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ito A, Ichiyanagi N, Ikeda Y, Hagiyama M,
Inoue T, Kimura KB, Sakurai MA, Hamaguchi K and Murakami Y:
Adhesion molecule CADM1 contributes to gap junctional communication
among pancreatic islet α-cells and prevents their excessive
secretion of glucagon. Islets. 4:49–55. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Murakami Y: Functional cloning of a tumor
suppressor gene, TSLC1, in human non-small cell lung cancer.
Oncogene. 21:6936–6948. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goto A, Niki T, Chi-Pin L, Matsubara D,
Murakami Y, Funata N and Fukayama M: Loss of TSLC1 expression in
lung adenocarcinoma: Relationships with histological subtypes, sex
and prognostic significance. Cancer Sci. 96:480–486. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hui AB, Lo KW, Kwong J, Lam EC, Chan SY,
Chow LS, Chan AS, Teo PM and Huang DP: Epigenetic inactivation of
TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog. 38:170–178.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Honda T, Tamura G, Waki T, Jin Z, Sato K,
Motoyama T, Kawata S, Kimura W, Nishizuka S and Murakami Y:
Hypermethylation of the TSLC1 gene promoter in primary gastric
cancers and gastric cancer cell lines. Jpn J Cancer Res.
93:857–860. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jansen M, Fukushima N, Rosty C, Walter K,
Altink R, Heek TV, Hruban R, Offerhaus JG and Goggins M: Aberrant
methylation of the 5′ CpG island of TSLC1 is common in pancreatic
ductal adenocarcinoma and is first manifest in high-grade PanlNs.
Cancer Biol Ther. 1:293–296. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fukuhara H, Kuramochi M, Fukami T,
Kasahara K, Furuhata M, Nobukuni T, Maruyama T, Isogai K, Sekiya T,
Shuin T, et al: Promoter methylation of TSLC1 and tumor suppression
by its gene product in human prostate cancer. Jpn J Cancer Res.
93:605–609. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Steenbergen RD, Kramer D, Braakhuis BJ,
Stern PL, Verheijen RH, Meijer CJ and Snijders PJ: TSLC1 gene
silencing in cervical cancer cell lines and cervical neoplasia. J
Natl Cancer Inst. 96:294–305. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takahashi Y, Iwai M, Kawai T, Arakawa A,
Ito T, Sakurai-Yageta M, Ito A, Goto A, Saito M, Kasumi F and
Murakami Y: Aberrant expression of tumor suppressors CADM1 and 4.1B
in invasive lesions of primary breast cancer. Breast Cancer.
19:242–252. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuramochi M, Fukuhara H, Nobukuni T, Kanbe
T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura
T, et al: TSLC1 is a tumor-suppressor gene in human non-small-cell
lung cancer. Nat Genet. 27:427–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagata M, Sakurai-Yageta M, Yamada D, Goto
A, Ito A, Fukuhara H, Kume H, Morikawa T, Fukayama M, Homma Y and
Murakami Y: Aberrations of a cell adhesion molecule CADM4 in renal
clear cell carcinoma. Int J Cancer. 130:1329–1337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jang SM, Sim J, Han H, Ahn HI, Kim H, Yi
K, Jun YJ, Rehman A, Chung MS, Jang K and Paik SS:
Clinicopathological significance of CADM4 expression in invasive
ductal carcinoma of the breast. J Clin Pathol. 66:681–686. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jang SM, Han H, Jun YJ, Jang SH, Min KW,
Sim J, Ahn HI, Lee KH, Jang KS and Paik SS: Clinicopathological
significance of CADM4 expression, and its correlation with
expression of E-cadherin and Ki-67 in colorectal adenocarcinomas. J
Clin Pathol. 65:902–906. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saito M, Goto A, Abe N, Saito K, Maeda D,
Ohtake T, Murakami Y and Takenoshita S: Decreased expression of
CADM1 and CADM4 are associated with advanced stage breast cancer.
Oncol Lett. 15:2401–2406. 2018.PubMed/NCBI
|
|
21
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sobin LH, Gospodarowicz M and Wittekind
Ch: International Union Against Cancer (UICC) TNM Classification of
Malignant Tumors. 7th edition. Wiley-Blackwell; Oxford, UK:
2010
|
|
23
|
Saito M, Matsuzaki M, Sakuma T, Katagata
N, Watanabe F, Yamaguchi Y, Schetter AJ, Takenoshita S and Nomizu
T: Clinicopathological study of non-palpable familial breast cancer
detected by screening mammography and diagnosed as DCIS. Breast
Cancer. 21:140–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wikman H, Westphal L, Schmid F, Pollari S,
Kropidlowski J, Sielaff-Frimpong B, Glatzel M, Matschke J, Westphal
M, Iljin K, et al: Loss of CADM1 expression is associated with poor
prognosis and brain metastasis in breast cancer patients.
Oncotarget. 5:3076–3087. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abramson VG, Lehmann BD, Ballinger TJ and
Pietenpol JA: Subtyping of triple-negative breast cancer:
Implications for therapy. Cancer. 121:8–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Abramson VG and Mayer IA: Molecular
heterogeneity of triple negative breast cancer. Curr Breast Cancer
Rep. 6:154–158. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kanke Y, Shimomura A, Saito M, Honda T,
Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu
C, et al: Gene aberration profile of tumors of adolescent and young
adult females. Oncotarget. 9:6228–6237. 2017.PubMed/NCBI
|
|
28
|
Greaves M and Maley CC: Clonal evolution
in cancer. Nature. 481:306–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang J, Fujimoto J, Zhang J, Wedge DC,
Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, et al: Intratumor
heterogeneity in localized lung adenocarcinomas delineated by
multiregion sequencing. Science. 346:256–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
de Bruin EC, McGranahan N, Mitter R, Salm
M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan
AJ, et al: Spatial and temporal diversity in genomic instability
processes defines lung cancer evolution. Science. 346:251–256.
2014. View Article : Google Scholar : PubMed/NCBI
|
